Edwin Yee, MD
Internal Medicine · Honolulu, HINPI 1851409270
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 437 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Amarin Pharma, Inc. at 26.1% of the total. Reporting peaked in 2021 at $1,917 and has fallen 73.2% since, to $513 in 2025. Among internal medicine clinicians in HI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 437 payments — averaging $21.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$2K
- AstraZeneca$2K
- Bayer$1K
- Novo Nordisk$858
- Amgen$741
- GSK$413
- plus $1K from 10 others
What the payments were for
- Food & beverage$9,360100%
- Education$440%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 103 | $2,453 |
| AstraZeneca | 106 | $2,241 |
| Bayer | 56 | $1,313 |
| Novo Nordisk | 49 | $858 |
| Amgen(2 entities) | 34 | $741 |
| GSK | 25 | $413 |
| Boehringer Ingelheim | 17 | $377 |
| Lilly USA, LLC | 19 | $376 |
| Kowa Pharmaceuticals America, Inc. | 9 | $192 |
| Novartis | 7 | $167 |
| Esperion Therapeutics, Inc. | 6 | $146 |
| Abbott | 2 | $47 |
| Exact Sciences | 1 | $27 |
| Genentech USA, Inc. | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$290
How this compares
$9,404 in reported general payments places this provider in the 90th percentile of 655 internal medicine providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 114 | $156,764 |
| JardianceEmpagliflozin | 78 | $121,960 |
| Xigduo XrDapaglifloz Propaned/Metformin | 70 | $93,812 |
| KerendiaFinerenone | 54 | $78,834 |
| OzempicSemaglutide | 44 | $77,454 |
| RybelsusSemaglutide | 39 | $68,201 |
| EliquisApixaban | 37 | $57,465 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 51 | $51,564 |
| ProliaDenosumab | 26 | $45,291 |
| VascepaIcosapent Ethyl | 54 | $43,123 |
| JanuviaSitagliptin Phosphate | 22 | $32,694 |
| MounjaroTirzepatide | 11 | $31,915 |
| Rosuvastatin Calcium | 372 | $19,653 |
| SynjardyEmpagliflozin/Metformin Hcl | 14 | $15,380 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $14,066 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $377 | $188,904143 claims |
| AstraZenecaFarxiga | $2,241 | $156,764114 claims |
| Novo NordiskOzempic, Rybelsus | $858 | $145,65483 claims |
| BayerKerendia | $1,313 | $78,83454 claims |
| MerckJanuvia, Janumet Xr | $14 | $46,76034 claims |
| AmgenProlia | $741 | $45,29126 claims |
| Lilly USA, LLCMounjaro | $376 | $31,91511 claims |
| GSKTrelegy Ellipta | $413 | $10,04612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 655 internal medicine providers in Hawaii.
Other internal medicine in Honolulu
- Keith WooHonolulu$106K
- Ronald PerryHonolulu$102K
- Laurie TomHonolulu$95K
- Yusuke MiyataniHonolulu$80K
- Joshua TanHonolulu$76K
- Jose de LeonHonolulu$52K
- Peter DeeHonolulu$49K
- James LumengHonolulu$45K
- Charles ZerezHonolulu$44K
- Anthony HernandezHonolulu$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.